相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anticancer activity, topoisomerase I inhibition, DNA 'light switch' behavior and molecular docking of two ruthenium complexes containing phenazine ring
Xue-Wen Liu et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α
Yingjie Qi et al.
DRUG DELIVERY (2021)
Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs
Emma Baglini et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
A patent review of topoisomerase I inhibitors (2016-present)
Asier Selas et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise
Noura Khaiwa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models
Keith T. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB
Alessio Ottaviani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation
Victor Gonzalez-Ruiz et al.
PHARMACEUTICS (2021)
The benzylisoquinoline alkaloids, berberine and coptisine, act against camptothecin-resistant topoisomerase I mutants
Naomi Inoue et al.
SCIENTIFIC REPORTS (2021)
Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo
Monize M. da Silva et al.
INORGANIC CHEMISTRY (2021)
Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B)
Asier Selas et al.
PHARMACEUTICALS (2021)
Targeting cancer with antibody-drug conjugates: Promises and challenges
Alexis Q. Dean et al.
MABS (2021)
Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer Related Targets
Ziga Skok et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
From coins to cancer therapy: Gold, silver and copper complexes targeting human topoisomerases
Jessica Ceramella et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems
Ali Dehshahri et al.
PHARMACOLOGICAL RESEARCH (2020)
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Synthesis of novel hybrid quinolino[4,3-b][1,5]naphthyridines and quinolino[4,3-b][1,5]naphthyridin-6(5H)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives
Endika Martin-Encinas et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Is the Way to Fight Cancer Paved with Gold? Metal-Based Carbene Complexes with Multiple and Fascinating Biological Features
Domenico Iacopetta et al.
PHARMACEUTICALS (2020)
Inhibition of histone deacetylases, topoisomerases and epidermal growth factor receptor by metal-based anticancer agents: Design & synthetic strategies and their medicinal attributes
Manpreet Kaur et al.
BIOORGANIC CHEMISTRY (2020)
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
Keith T. Schmidt et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Development of a metabolically stable topoisomerase I poison as anticancer agent
Biswajit Kundu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent
Shu Fan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Evodiamine: A review of its pharmacology, toxicity, pharmacokinetics and preparation researches
Qiang Sun et al.
JOURNAL OF ETHNOPHARMACOLOGY (2020)
Antitumor functions and mechanisms of nitidine chloride in human cancers
Yue Cui et al.
JOURNAL OF CANCER (2020)
Novel phosphine sulphide gold(i) complexes: topoisomerase I inhibitors and antiproliferative agents
Endika Martin-Encinas et al.
DALTON TRANSACTIONS (2020)
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma A Phase 2 Clinical Trial
Daniel V. T. Catenacci et al.
JAMA NETWORK OPEN (2020)
Synthesis, characterization, DNA binding, topoisomerase I inhibition and antiproliferation activities of three new functionalized terpyridine platinum (II) complexes
Keke Chai et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2019)
Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity
Alexandra Zakharenko et al.
MEDICINAL RESEARCH REVIEWS (2019)
Targeting Topoisomerase I in the Era of Precision Medicine
Anish Thomas et al.
CLINICAL CANCER RESEARCH (2019)
A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade
Xiaoxia Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Laetitia Marzi et al.
CLINICAL CANCER RESEARCH (2019)
Straightforward synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents of hybrid Chromeno[4,3-b][1,5]Naphthyridines and Chromeno[4,3-b][1,5]Naphthyridin-6-ones
Endika Martín-Encinas et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Irinotecan: 25 years of cancer treatment
Christian Bailly
PHARMACOLOGICAL RESEARCH (2019)
Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries
Maris A. Cinelli
MEDICINAL RESEARCH REVIEWS (2019)
Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding
Monize M. da Silva et al.
DALTON TRANSACTIONS (2019)
New anthrahydrazone derivatives and their cisplatin-like complexes: synthesis, antitumor activity and structure-activity relationship
Rui-Xue Liu et al.
NEW JOURNAL OF CHEMISTRY (2019)
Polymer conjugated graphene-oxide nanoparticles impair nuclear DNA and Topoisomerase I in cancer
Aditi Nandi et al.
NANOSCALE ADVANCES (2019)
Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity
Concepcion Alonso et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Silver pyridine-2-sulfonate complex - its characterization, DNA binding, topoisomerase I inhibition, antimicrobial and anticancer response
Michaela Rendosova et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2018)
New (arene)ruthenium(II) complexes of 4-aryl-4H-naphthopyrans with anticancer and anti-vascular activities
Florian Schmitt et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2018)
In vitro biological properties and predicted DNA-BSA interaction of three new dicyanidoargentate(I)-based complexes: synthesis and characterization
Ahmet Karadag et al.
NEW JOURNAL OF CHEMISTRY (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High Efficacy of Intravenous Gimatecan on Human Tumor Xenografts
Michelandrea De Cesare
ANTICANCER RESEARCH (2018)
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
Jenna H. Burton et al.
CLINICAL CANCER RESEARCH (2018)
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor
Seojeong Park et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Advantages of an optical nanosensor system for the mechanistic analysis of a novel topoisomerase I targeting drug: a case study
Marie B. Andersen et al.
NANOSCALE (2017)
Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
Geraldine Helen O'Sullivan Coyne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M. H. Voss et al.
ANNALS OF ONCOLOGY (2017)
New Acridine Thiourea Gold(I) Anticancer Agents: Targeting the Nucleus and Inhibiting Vasculogenic Mimicry
Sergio A. Perez et al.
ACS CHEMICAL BIOLOGY (2017)
The long story of camptothecin: From traditional medicine to drugs
Emanuela Martino et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs
Yeon Hee Park et al.
CANADIAN RESPIRATORY JOURNAL (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives
Zi-Long Song et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity
Concepcion Alonso et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of a novel anti-cancer agent targeting both topoisomerase I and II in hepatocellular carcinoma Hep 3B cells in vitro and in vivo: Cinnamomum verum component 2-methoxycinnamaldehyde
Daw-Shyong Perng et al.
JOURNAL OF DRUG TARGETING (2016)
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Yves Pommier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
Andrew J. Clark et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)
Brian B. Hasinoff et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Synthesis of novel 10-hydroxycamptothecin derivatives utilizing topotecan hydrochloride as ortho-quinonemethide precursor
Hanyi Tan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Design and synthesis of novel PEG-conjugated 20(S)-camptothecin sulfonylamidine derivatives with potent in vitro antitumor activity via Cu-catalyzed three-component reaction
Zi-Long Song et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Synthesis and Biological Evaluation of 1,5-Naphthyridines as Topoisomerase I Inhibitors. A New Family of Antiproliferative Agents
Concepcion Alonso et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2015)
Perspectives on Biologically Active Camptothecin Derivatives
Ying-Qian Liu et al.
MEDICINAL RESEARCH REVIEWS (2015)
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
David Westover et al.
MOLECULAR CANCER (2015)
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
P. Znojek et al.
BRITISH JOURNAL OF CANCER (2014)
A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability
Guillermo Rodriguez-Berna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives
Yu-Chuan Wang et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2014)
Effect of oxindolimine copper(II) and zinc(II) complexes on human topoisomerase I activity
Prafulla Katkar et al.
METALLOMICS (2014)
Drugging Topoisomerases: Lessons and Challenges
Yves Pommier
ACS CHEMICAL BIOLOGY (2013)
A Natural Anticancer Agent Thaspine Targets Human Topoisomerase IB
Silvia Castelli et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2013)
Gossypol Interferes with Both Type I and Type II Topoisomerase Activities Without Generating Strand Breaks
Muge Senarisoy et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2013)
Type IA topoisomerase inhibition by clamp closure
Majety Naga Leelaram et al.
FASEB JOURNAL (2013)
Gold(III) Complexes of Pyridyl- and Isoquinolylamido Ligands: Structural, Spectroscopic, and Biological Studies of a New Class of Dual Topoisomerase I and II Inhibitors
Colin R. Wilson et al.
INORGANIC CHEMISTRY (2013)
Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
G. L. Beretta et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Enhanced cytotoxicity of silver complexes bearing bidentate N-heterocyclic carbene ligands
Diana C. F. Monteiro et al.
DALTON TRANSACTIONS (2012)
The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
Masazumi Nagai et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Synthesis, Aqueous Reactivity, and Biological Evaluation of Carboxylic Acid Ester-Functionalized Platinum-Acridine Hybrid Anticancer Agents
Leigh A. Graham et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Identification, Synthesis, and Biological Evaluation of Metabolites of the Experimental Cancer Treatment Drugs Indotecan (LMP400) and Indimitecan (LMP776) and Investigation of Isomerically Hydroxylated Indenoisoquinoline Analogues as Topoisomerase I Poisons
Mans A. Cinelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations
Guoqiang Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action
Marcio Fronza et al.
PHYTOCHEMISTRY (2012)
Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells
Xiaobei Pan et al.
PHYTOMEDICINE (2012)
New Indolocarbazoles from a Mutant Strain of the Marine-Derived Actinomycete Streptomyces fradiae 007M135
Peng Fu et al.
ORGANIC LETTERS (2012)
Constituents with DNA Topoisomerases I and II Inhibitory Activity and Cytotoxicity from the Roots of Rubio cordifolia
Su-Yang Jeong et al.
PLANTA MEDICA (2012)
Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol
Ronald K. Blackman et al.
PLOS ONE (2012)
Inhibition of human DNA topoisomerase IB by a Cyclometalated Gold III compound: Analysis on the different steps of the enzyme catalytic cycle
Silvia Castelli et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2011)
Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
Danijela Jelovac et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment
Leslie S. Kurtzberg et al.
CLINICAL CANCER RESEARCH (2011)
Copper: An essential metal in biology
Richard A. Festa et al.
CURRENT BIOLOGY (2011)
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration
Emilie Roger et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2011)
G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity
Deborah S. Goldberg et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Darren Griffith et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors
Muhammad Wasif Saif et al.
ANTI-CANCER DRUGS (2010)
The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode
Maris A. Cinelli et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study
Arjun Basnet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons
Jessie Jing Yan et al.
CHEMICAL COMMUNICATIONS (2010)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
S. Salerno et al.
CURRENT MEDICINAL CHEMISTRY (2010)
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate et al.
DALTON TRANSACTIONS (2010)
Design, Synthesis, and Evaluation of Dibenzo[c,h][1,6]naphthyridines as Topoisomerase I Inhibitors and Potential Anticancer Agents
Evgeny Kiselev et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A Series of α-Amino Acid Ester Prodrugs of Camptothecin: In Vitro Hydrolysis and A549 Human Lung Carcinoma Cell Cytotoxicity
Manjeet Deshmukh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin
Mark E. Davis
ADVANCED DRUG DELIVERY REVIEWS (2009)
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer
Alexander V. Yurkovetskiy et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Yves Pommier
CHEMICAL REVIEWS (2009)
Novel camptothecin derivatives as topoisomerase I inhibitors
Serena Basili et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
Yves Pommier et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
Agnes L. -F. Chan et al.
MOLECULES (2009)
Semi-synthesis and biological activity of γ-lactones analogs of camptothecin
Mingzong Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Novel hexacyclic camptothecin derivatives. Part 1: Synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring
Sheng Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Natural inhibitors of DNA topoisomerase I with cytotoxicities
Hong-Jin Han et al.
CHEMISTRY & BIODIVERSITY (2008)
Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy
Yu-Ling Leu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance
Carmen Losasso et al.
NUCLEIC ACIDS RESEARCH (2008)
Topoisomerase I inhibitors: camptothecins and beyond
Yves Pommier
NATURE REVIEWS CANCER (2006)
Taspine:: Bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana
Judith M. Rollinger et al.
JOURNAL OF NATURAL PRODUCTS (2006)
Synthesis and biological assays of E-ring analogs of camptothecin and homocamptothecin
Raghuram S. Tangirala et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors
HC Pitot et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors
IELM Kuppens et al.
CLINICAL CANCER RESEARCH (2006)
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
Cesar Sanchez et al.
NATURAL PRODUCT REPORTS (2006)
Isatin-Schiff base copper(II) complexes and their influence on cellular viability
G Cerchiaro et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2005)
Molecular determinants of topoisomerase I poisoning by lamellarins: Comparison with camptothecin and structure-activity relationships
E Marco et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex
BL Staker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours
NE Schoemaker et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones:: Variation of N-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance
AL Ruchelman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on solubility of camptothecin
AM Sætern et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Luotonin A. A naturally occurring human DNA topoisomerase I poison
A Cagir et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I
P Fiorani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin
P Hautefaye et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents
D Makhey et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Camptothecin delivery methods
A Hatefi et al.
PHARMACEUTICAL RESEARCH (2002)
Crystal structure of a complex of a type IA DNA topoisomerase with a single-stranded DNA molecule
A Changela et al.
NATURE (2001)
分享论文
